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Abstract
 
The hypothesis that FasL expression by tumor cells may impair the in vivo efficacy of antitumor
immune responses, through a mechanism known as ‘Fas tumor counterattack,’ has been recently
questioned, becoming the object of an intense debate based on conflicting results. Here we def-
initely show that FasL is indeed detectable in the cytoplasm of melanoma cells and its expression
is confined to multivesicular bodies that contain melanosomes. In these structures FasL colocalizes
with both melanosomal (i.e., gp100) and lysosomal (i.e., CD63) antigens. Isolated melanosomes
express FasL, as detected by Western blot and cytofluorimetry, and they can exert Fas-mediated
apoptosis in Jurkat cells. We additionally show that melanosome-containing multivesicular bod-
ies degranulate extracellularly and release FasL-bearing microvesicles, that coexpress both gp100
and CD63 and retain their functional activity in triggering Fas-dependent apoptosis of lymphoid
cells. Hence our data provide evidence for a novel mechanism potentially operating in Fas tu-
mor counterattack through the secretion of subcellular particles expressing functional FasL. Such
vesicles may form a sort of front line hindering lymphocytes and other immunocompetent cells
from entering neoplastic lesions and exert their antitumor activity.
Key words: melanoma • apoptosis • T cells • melanosome • microvesicles
 
Introduction
 
Despite the existence of specific T lymphocytes recogniz-
ing tumor cells is now well established, a clear understand-
ing of the functional status of these cells in vivo, and their
impact on tumor growth has been so far elusive. In con-
trast, several factors have been described that potentially
contribute to tumor cell evasion of the immune response
(1), suggesting that potential antitumor activity of immune
effectors may be impaired by mechanisms that ultimately
result in tumor progression.
One of the strategies of tumor immune escape is repre-
sented by the acquisition of FasL expression that may en-
able cancer cells to deliver death signals to activated Fas-
positive T lymphocytes (2, 3). FasL is a transmembrane
type II protein belonging to the TNF protein superfamily,
that plays a pivotal role in the induction of receptor (Fas)-
mediated apoptosis. In fact, Fas–FasL interaction regulates
important immune functions such as downmodulation of
immunological responses, T cell activation–induced cell
death, clonal downsizing, and control of peripheral toler-
ance to self-antigens (4). Apart from immunocompetent
cells, FasL expression is additionally well documented in
organs such as eye, central nervous system, and testis
where it is thought to contribute to the maintenance of
these immune privileged sites (4). Due to the functional
properties of this molecule, it has been thus hypothesized
that tumor cells could take advantage of FasL expression for
mediating apoptosis of antitumor-activated T cells. Many
authors have indeed shown that tumor cells of different his-
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totypes (melanoma, colon, breast, esophageal cancers) do
acquire FasL expression as detected both in vivo and in
vitro (3). Additionally, such expression has been reported
to negatively correlate with patient prognosis when evalu-
ated on breast, ovarian, liver cancers, and melanoma speci-
mens (3, 5, 6).
Although intriguing, this hypothesis is currently under
evaluation, animating a debate based on controversial is-
sues, such as the specificity of the different antibodies avail-
able for FasL detection or the usage of nonintron spanning
primers for FasL detection by RT-PCR. The presence of
infiltrating FasL-positive lymphocytes in tumor lesions has
been additionally hypothesized to interfere with ex vivo
FasL staining (7–10).
However, the recent use of specific reagents for the de-
tection of FasL has indeed confirmed the expression of FasL
in some tumor cell types (9, 11). Moreover, the concomi-
tant presence of apoptotic T cells in FasL-expressing tu-
mors (12, 13) and the negative prognostic role of FasL ex-
pression by neoplastic cells (5, 6, 14) suggest a potential
efficacy of tumor counterattack in influencing in vivo tu-
mor progression.
A relevant mechanism of FasL trafficking, occurring in
NK cells and CTL, has been recently reported as involving
specific intracellular transport of FasL on lysosomal-like
vesicles that are unidirectionally polarized on the mem-
brane of NK and T cells (15, 16) and a mechanism based
on the release of FasL-bearing microvesicles (MVs)
 
*
 
 has
been also described to occur in FasL transfected cells (17).
Indeed, melanoma cells contain specialized granules (mela-
nosomes), which are the site of synthesis and storage of
melanin and related molecules. These organelles have been
clearly demonstrated to share phenotypic and functional
features with lysosome vesicles and lytic granules (18). Ad-
ditionally, a secretory pathway has been described in mela-
noma cells that involves multivesicular bodies (MVB)
containing MVs which express tumor antigens such as
MART-1 and tyrosinase (19). The physiologic fate of these
vesicles is to be injected by melanocytes into keratinocytes
in order to transfer melanin pigments.
On the basis of these data, we have reevaluated the role
of FasL in tumor immune escape, taking into account the
possibility that melanoma cells may share FasL expression
pathway and intracellular trafficking with immunocompe-
tent cells. Expression of FasL in melanoma cells was thus
studied by investigating FasL localization in cytoplasmic or-
ganelles of various human melanoma cell lines and its possi-
ble implication in the counterattack of melanoma against
immune cells. Here we report that melanoma cells do ex-
press FasL intracellularly, with a localization confined to
MVB that contains melanosomes. FasL-bearing MVs can
be released extracellularly, retaining their FasL expression
and proapoptotic activity on Fas-sensitive lymphoid cells.
 
Materials and Methods
 
Antibodies and FACS
 
®
 
 Analysis.
 
Cellular expression of FasL
was evaluated after 24-h treatment with 10 
 
 
 
M KB8301 (4-[N-
hydroxyamino]-2R-isobutyl-3S-methylsuccinyl)-L-3-[5,6,7,8-
tetrahydro-1-naphthyl] alanine-N-methylamide; BD PharMin-
gen), a metalloproteinase inhibitor known to block soluble FasL
release (20). Wild-type and FasL-transfected 293 cells (transiently
transfected using a DNA plasmid provided by H. Eibel, Clinical
Research Unit for Rheumatology, University Hospital Freiburg,
Germany) were used as negative and positive controls, respec-
tively. After mechanical detachment, cells were stained with anti-
FasL mAbs (clone G247 and clone NOK-1; both from BD
PharMingen), recognizing two different epitopes of the FasL mol-
ecule, and with FITC-conjugated goat anti–mouse IgG (Bio-
source International). As negative control, an isotype-matched
mAb followed by the FITC-conjugated anti–mouse IgG was
used. Intracellular staining for detection of FasL was performed by
previous permeabilization of melanoma cells with 70% methanol
(at 4
 
 
 
C for 5 min) followed by incubation with anti-FasL G247
and FITC-conjugated anti–mouse IgG. Fluorescence was then
analyzed by FACSCalibur™ flow cytometer (Becton Dickinson)
and CELLQuest™ software (Becton Dickinson). Staining of mela-
nosomes  and MVs was additionally performed with anti–lyso-
some-associated membrane protein (LAMP)-2, anti-CD63 (both
from BD PharMingen), and anti-gp100 (Immunotech) mAbs, fol-
lowed by incubation with FITC goat anti–mouse IgG (Biosource
International). An irrelevant isotype-matched mAbs (anti–TCR-
 
  
 
; Becton Dickinson), followed by the FITC-conjugated anti–
mouse IgG, was used as negative control. Melanosomes and
 
 MVs
 
were resuspended in 0.1 
 
 
 
-filtered PBS (100 
 
 
 
l per sample) and
primary mAb were added at a concentration of 10–30 
 
 
 
g/ml. Af-
ter 1 h at 4
 
 
 
C, samples were then incubated with FITC-conju-
gated anti–mouse IgG (10 
 
 
 
g/ml) for 30 min at 4
 
 
 
C. Labeled
melanosome and microvesicle suspensions were then diluted to
300 
 
 
 
l with filtered PBS and samples were analyzed by FACSCal-
ibur™ and CELLQuest™ software. Melanosomes were detected
as granules of the approximate mean size of 1 
 
 
 
m, while
 
 MVs
 
had a size range of 100–600 nm, relative to standard beads of 6
 
 
 
m size (CaliBRITE beads; Becton Dickinson).
 
Immunocytochemistry.
 
Human melanoma cells were attached
to poly-
 
L
 
-lysine-covered glass chamber slides (Labtek) or spun
onto glass slides (Shandon), as appropriate, fixed with 70% etha-
nol (EtOH) 10 min at 4
 
 
 
C, and stained by immunocytochemistry
for anti-FasL (clones G247 and NOK-1) using the alkaline phos-
phatase anti-alkaline phosphatase (Dako) method or the peroxi-
dase-anti-peroxidase (PAP) (Dako) method, in single and double
staining, as appropriate (21). In single staining, cells were coun-
terstained with Mayer’s haematoxylin.
 
Electron and Immunoelectron Microscopy.
 
For transmission elec-
tron microscopy, melanoma cells, fixed with 2.5% glutaralde-
hyde, and postfixed in 1% OsO
 
4
 
, were dehydrated in alcohol and
embedded in epoxy resin. For immunoelectron microscopy cells
were fixed, after two washes in 0.1 M cacodylate buffer, with 3%
paraformaldehyde in 0.1 M cacodylate buffer for 2 h. Then, they
were embedded in 2% agar Noble in H
 
2
 
O, at 37
 
 
 
C. For subse-
quent embedding, the samples were dehydrated with increasing
concentrations of EtOH. Infiltration of the samples was per-
formed with increasing concentrations of Lowicryl HM20 resin
(Taab) in 100% EtOH and finally in pure Lowicryl. The poly-
merization was performed in beem capsules by indirect UV irra-
diation (360 nm) at 4
 
 
 
C. For FasL immunolocalization in
postembedding procedure, thin sections, collected on gold grids,
were treated for 5 min with PBS containing 0.15% (wt/vol) gly-
 
*
 
Abbreviations used in this paper:
 
 ER, endoplasmic reticulum; EtOH, etha-
nol; LAMP, lysosome-associated membrane protein; MVB, multivesicu-
lar bodies; MV, microvesicle; PAP, peroxidase-anti-peroxidase; PI, pro-
pidium iodide. 
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cin. After washing by quickly floating the grids on PBS drops
containing 0.1% (wt/vol) BSA (Sigma-Aldrich), the sections were
incubated overnight at 4
 
 
 
C with mAb G247 (1:10 diluted). After
washing by floating the grids on PBS drops containing 0.1% (wt/
vol) BSA for 1 h at room temperature, the sections were preincu-
bated with PBS 0.1% (wt/vol) BSA for 10 min, washed in PBS
containing 0.1% (wt/vol) BSA, and then labeled with a goat anti–
mouse IgG 10-nm gold conjugate (1:10 diluted; Sigma-Ald-
rich) for 20 min, then washed in PBS containing 0.1% BSA for
20 min at room temperature. As negative control, sections were
incubated with an irrelevant isotype-matched mAb or with a goat
anti–mouse IgG gold alone.
For ultrathin cryosections cells were fixed with 4% paraformal-
dehyde plus 0.1% glutaraldehyde in PBS, pH 7.4, for 2 h at 4
 
 
 
C,
washed, and embedded in 2% agarose low melting point (LMP)
that was solidified on ice. Agarose blocks were infused with 2.3 M
sucrose in PBS for 3 h at 4
 
 
 
C, frozen in LN
 
2
 
, and cryosec-
tioned following the method by K.T. Tokuyasu (22), as described
previously (23). Ultrathin cryosections were collected using su-
crose and methyl-cellulose and incubated with specific mAb, then
revealed with protein A-gold conjugates of different size (10 or
20 nm, as appropriate). Finally, ultrathin cryosections were
stained with the solutions of 2% methylcellulose and 0.4% uranyl
acetate before EM examination.
For electron microscopy of the isolated microvescicles, drop-
lets of RPMI 1640 with suspended membranes from 70,000
 
 g
 
pellets were fixed with 2% paraformaldehyde in PBS and put on
thin carbon film-coated grids for TEM observation and air-dried.
FasL labeling was performed by the immunonegative stain tech-
nique. Briefly, the grids were incubated at 4
 
 
 
C overnight with
the anti–human FasL mAb, G247, diluted 1:10, in PBS contain-
ing 1.0% BSA (Sigma-Aldrich). After washing with PBS, the
grids were incubated with anti–mouse IgG-gold conjugate
(Sigma-Aldrich; average diameter of gold particles 5 nm), and di-
luted 1:10 in PBS at room temperature for 1 h. Negative controls
were performed by incubating samples with anti–mouse IgG
 
2a
 
 or
with immunoconjugate alone (data not shown). After washing
with PBS, grids were negatively stained with 2.0% aqueous phos-
photungstic acid for 2 min. Samples were examined with a Phil-
ips 208 transmission electron microscope (FEI Company).
 
Immunoprecipitation.
 
Adherent melanoma cells (10
 
6
 
) were sur-
face-labeled with sulfo-
 
N
 
-hydroxysuccinimide-biotin according
to the manufacturer’s instructions (Amersham Pharmacia Biotech).
After extensive washing, the cells were lysed with lysing buffer
(1% Triton X-100, 150 mM NaCl, 1 mM Tris-HCl, 1 mM
EDTA, 1 mM EGTA, 1 mM PMSF, 10 
 
 
 
g/ml aprotinin, 10 
 
 
 
g/
ml leupeptin, and 30 
 
 
 
g/ml KB8301).
Proteins corresponding to 10
 
6
 
 cells equivalent were used for
each specific immunoprecipitation. After preclearing with control
mouse IgG, the supernatant was specifically immunoprecipitated
using 2 
 
 
 
g/ml of NOK-1, G247 (BD PharMingen), W6.32 (an
anti–HLA-class I monomorphic determinant), or control mouse
IgG1. After washing with lysing buffer, the eluates were subjected
to SDS-PAGE and electroblotted. The membrane was then incu-
bated with strepavidin-HPR and developed with ECL detection
system (Amersham Pharmacia Biotech).
 
Supernatants, Total Cell Lysates, Cytoplasmic-enriched Preparations
and Isolation of Melanosomes, and MVs.
 
Supernatants from mela-
noma cell lines were harvested from 72 h confluent melanoma
cell cultures, concentrated with centrifuge filter devices, Centri-
con (Millipore), with a cut off of 50 kD to enrich for soluble
molecules 
 
 
 
50 kD, aliquoted, and stored at 
 
 
 
80
 
 
 
C. Jurkat cells
(4 
 
 
 
 10
 
5
 
 cells per milliliter) were stimulated with 50 
 
 
 
g/ml PHA
 
for 5 min; after PHA removal by centrifugation and washing,
they were resuspended in complete medium and cultured at
37
 
 
 
C for 1 h (16). Supernatants from resting or activated cells
were collected, concentrated, and stored as described previously.
Total cell lysates were obtained lysing cells by an hypotonic
solution (10 mM hepes, pH 6.9, 10 mM KCl, 0.3% aprotinin,
and 0.1 mM PMSF), extensively homogenizing using a Potter-
Elvehjem homogenizer and centrifuging the suspension for 10
min at 600 
 
g
 
. Total cell lysates were obtained from confluent
melanoma cell cultures or from Jurkat cells, activated as described
previously. Cytoplasm-enriched preparations were prepared by
differential centrifugation starting from the homogenate. After 3
min at 1,000 
 
g
 
 at 4
 
 
 
C, the supernatant containing cytoplasma, cy-
toskeleton and membrane fractions was centrifuged at 11,000 
 
g
 
for 30 min at 4
 
 
 
C in order to separate the cytoplasma (superna-
tant) from cell surface membranes and cytoskeleton (pellet).
Isolation of melanosomes was performed as described previ-
ously (24). Briefly, the homogenate from 10
 
9
 
 melanoma cells re-
suspended in a solution of 0.25 M sucrose, underwent serial cen-
trifugations (600
 
 g
 
 for 10 min 
 
 
 
 2; 11,000 
 
g
 
 for 10 min 
 
 
 
 2).
The sediment was then suspended in 0.25 M sucrose. The sus-
pension was layered over 1.7 M sucrose and centrifuged at
37,000 
 
g
 
 for 1 h using the swing-out SW 41 rotor of the Beck-
man ultracentrifuge (Beckman Coulter). The sediment was sus-
pended in 0.25 M sucrose, layered over 2.0 M sucrose, and cen-
trifuged again at 37,000 
 
g
 
 for 1 h. The obtained sediment
contained isolated melanosomes.
Microvesicles from melanoma and resting/PHA-activated Jur-
kat cells were separated according to Martinez-Lorenzo et al.
(16). After centrifugation at 10,000 
 
g
 
 for 30 min at 4
 
 
 
C, the ob-
tained supernatant was further ultracentrifugated at 100,000 
 
g
 
 for
18 h at 4
 
 
 
C. The pellet, containing isolated MVs, was then resus-
pended in appropriate medium according to following treat-
ments. Quantification of total proteins contained in melanosome
or microvesicle preparations was evaluated by Lowry assay (Bio-
Rad Laboratories) on organelle lysates. The mean protein recov-
ery was 0.98 mg (range 0.28–1.7) for melanosomes, and 0.75 mg
(range 0.31–1.2) for exosome-derived vesicles.
 
Western Blot Analysis.
 
Supernatants, total cell lysates, and sub-
cellular fractions (cytoplasma, melanosomes, and microvesicles)
from melanoma and Jurkat cells were analyzed for FasL protein
expression by Western blot analysis. Isolated melanosomes and
microvesicles were resuspended in lysis buffer (1% Triton X-100,
0.1% SDS in 0.1 M Tris/HCL, pH 7) with the addition of the 10
 
 
 
M matrix metalloproteinase inhibitor KB8301 (BD PharMin-
gen). After protein determination using the Lowry assay (Bio-
Rad Laboratories), 75 
 
 
 
g of total protein of the different prepara-
tions were boiled for 6 min in SDS sample buffer containing
 
 
 
-mercaptoethanol, separated on a 10% SDS-PAGE, and then elec-
troblotted onto a PVDF membrane. As a positive control 1 ng of
rFasL (Alexis) was used. The membrane was stained using 2 
 
 
 
g/
ml anti–human FasL mAb G247, developed with a secondary
mouse anti–human IgG conjugated to horseradish peroxidase
(BD Transduction Laboratories), and detected by SuperSignal de-
tection system (Pierce Chemical Co.).
To further check purity of melanosome and microvesicle
preparations, the following additional molecules were analyzed in
Western blot analysis under reducing conditions: gp100 (on a
15% SDS-PAGE gel) protein; and markers specific for endoplas-
tic reticulum, Golgi, mitochondria, and plasma membrane. The
following mAb were used: anti–human gp100/pmel17 (clone
HMB45; Dako); BiP/GRP78 (BD Transduction Laboratories);
GM130 (BD Transduction Laboratories); mitochondria (clone 
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MAB1273; Chemicon International, Inc.); HLA-class I (L31;
provided by P. Giacomini, Istituto Regina Elena, Rome, Italy);
and anti–caveolin-1 (Santa Cruz Biotechnology, Inc.).
To exclude any possible contamination, isolated microvesicles
from FBS and from RPMI supplemented with 10% FBS were
also analyzed for FasL expression in Western blot analysis, but the
protein was never detected (data not shown).
 
Analysis of Apoptotic Activity.
 
Quantitative assessment of apop-
tosis was performed by cytofluorimetric analysis of propidium io-
dide (PI)-stained cells as described previously (25) with minor
modifications and by annexin V binding assay. The occurrence of
apoptosis was also monitored by Western blot analysis of cas-
pase-8 activation. Briefly, Jurkat cells (10
 
6
 
 cells per milliliter) were
seeded in 24-well plates in 10% FBS RPMI 1640. rFasL at the
concentration of 50–100 ng/ml or different concentrations of
melanosomes or microvesicles were added. For assessing Fas-
involvement, cells were preincubated for 30 min at 42
 
 
 
C with
different concentrations of anti-Fas mAb (ZB4; Upstate BioTech-
nology). Apoptosis was analyzed after 15–18-h incubation. For
analysis of PI-staining, PBS-washed cells were suspended in hy-
potonic solution containing 10 
 
 
 
g/ml PI, 0.1% sodium citrate,
0.1% Triton X-100, and RNase A (66 U/ml), and incubated 4 h
at 4
 
 
 
C. The red fluorescence of individual nuclei was measured
with a FACSCalibur™ flow cytometer (Becton Dickinson). An-
nexin V binding was measured using the Annexin V-Biotin Apop-
tosis Detection kit (Oncogene Research Products) according to
manufacturer’s instructions. After the final incubation in binding
buffer containing FITC-streptavidin (Amersham Pharmacia Bio-
tech) and PI (0.6 
 
 
 
g/ml), cells were incubated on ice and imme-
diately analyzed by flow cytometry. Caspase-8 activation was
monitored by the appearance of the activated form of 40 kD, us-
ing Western blot analysis. Proteins were separated on SDS-PAGE
and immunoblotted. The nitrocellulose membrane was then in-
cubated overnight at 4
 
 
 
C with a polyclonal Ab to caspase-8 (BD
PharMingen). A rabbit antiactin Ab was used as control for load-
ing. Ab binding was detected by enhanced chemiluminescence
(Amersham Pharmacia Biotech).
For detecting lymphocyte FasL-mediated apoptosis induced by
tumor cells, melanoma cells (at 10
 
5
 
 cells per well, in U-bottomed
96-well plates) were cultured in 10% FBS RPMI 1640 for 2 h at
37
 
 
 
C, for allowing cell adhesion. 
 
51
 
[Cr]-labeled Jurkat cells (at 10
 
3
 
cells per well), in the presence or absence of neutralizing anti-Fas
mAb ZB4 (50 ng/ml), were then added as target cells and the
plates were incubated for 16 h 0.50 
 
 
 
l per well of supernatant
were harvested, counted, and killing was calculated as percentage
of lysis (26). Comparable results were obtained using targets la-
beled with 
 
3
 
[H]-TdR or 
 
125
 
IdU (data not shown). Melanoma su-
pernatant was harvested from 72 h confluent melanoma cell cul-
tures, concentrated with centrifuge filter devices, Centricon
(Millipore), with a cut off of 50 kD to enrich for soluble mole-
cules 
 
 
 
50 kD, aliquoted, and stored at 
 
 
 
80
 
 
 
C. Different dilu-
tions of supernatant (starting from 1:2) were added to the cyto-
toxic assay. rFasL (at 100 ng/ml) was also used as positive control.
 
Results
 
FasL Intracellular Expression in Melanoma Cells.
 
To study
the expression of FasL in melanoma cells, we first investi-
gated the presence of this molecule at melanoma cell sur-
face level. To avoid significant FasL release by metallo-
proteases, cells were pretreated with the metalloprotease
inhibitor KB8301, which has been shown to effectively in-
hibit FasL shedding from cell membrane (20). As reported
in Fig. 1 A, none of the melanoma lines examined ex-
pressed detectable levels of FasL molecules on their cell sur-
face, as evaluated by staining with NOK-1 mAb, known to
specifically recognize FasL (9, 27, 28). As positive control, a
Figure 1. FasL cannot be de-
tected on melanoma cell mem-
brane and in culture supernatant.
(A) Cytofluorimetric analysis.
Melanoma and transiently FasL-
gene transfected 293 cells (con-
trol) were stained with anti-FasL
NOK-1 mAb (dark area), or
with an isotype-matched IgG
(clear area), after 24 h-treatment
with KB8301 10  M; fluores-
cence was analyzed by FACS-
Calibur™ and CELLQuest™
software; data refer to three rep-
resentative melanoma lines, from
a panel of 10 tested. (B) Immu-
noprecipitation of membrane
proteins: cell surface biotin-
labeled cells of Me15392 were
immunoprecipitated with G247
(lane 2) and NOK-1 (lane 3)
anti-FasL mAb, with the isotype-
matched murine IgG1 negative
control (lane 4), or with the anti–HLA-class I mAb W6.32, as positive control. Cell lysates were analyzed in Western blot analysis with Streptavidin-HPR.
A specific band (44 kD) is detectable only in lysates immunoprecipitated with W6.32 (lane 1). (C) Proapoptotic activity of melanoma cells. 51[Cr]-labeled
Jurkat cells (at 103cells per well), in the presence or absence of neutralizing anti-Fas mAb ZB4 (50 ng/ml), were incubated for 16 h with either melanoma
cells (105cells per well), rFasL (100 ng/ml), or concentrated supernatant from 501mel culture (dilution 1:2). Killing was calculated as percentage of lysis.
(D) Western blot analysis of FasL expression in supernatants from melanoma cell cultures. Melanoma supernantants were harvested from 72 h confluent
cell cultures and concentrated by Centricon filter devices (cut-off 50 kD) (lanes 2 and 3). Concentrated supernatant from resting (lane 4) or PHA-activated
(lane 5) Jurkat cells were additionally used as negative and positive controls, respectively. rFasL was also included (lane 1). Western blot analysis was stained
with the anti-FasL G247 mAb. A 27-kD band, corresponding to soluble FasL, could be detected in supernatant from PHA-activated Jurkat cells.1307 Andreola et al.
population of FasL-positive cells could be identified by the
same Ab in FasL-gene transfected but not in wild-type 293
cells (Fig. 1 A). Comparable data were obtained with an-
other specific anti-FasL mAb (G247) (9, 27, 28, and data
not shown). The absence of detectable levels of FasL on the
cell surface was confirmed by immunoprecipitation of cell
surface biotin-labeled proteins using both G247 mAb and
NOK-1. As shown in Fig. 1 B (lanes 2 and 3), no specific
Figure 2. Immunocytochemical analysis of FasL ex-
pression in human melanoma cells. FasL expression in
three representative melanoma lines (Me15392, 501mel,
and Me30966, in A, B, and C, respectively), from a panel
of 10 tested, is shown. Note (i) the striking localization of
the FasL staining on well-defined cytoplasmic vesicles and
(ii) the differential quantitative expression among the three
cell lines. Immunophenotyping of fixed cells was per-
formed using the PAP method. AEC was used as chro-
mogen and Mayer’s haematoxylin for the counterstaining.
Original magnification: 2,500 .1308 Tumor Counterattack through FasL-bearing Melanosome-related Vesicles
band compatible with FasL molecule could be precipitated
from melanoma cell membranes. The same gel developed
by the isotype IgG1 control mAb failed to show any band
(Fig. 1 B, lane 4). As control of cell surface labeling and
immunoprecipitation procedures, HLA-class I molecules
were immunoprecipitated by W6.32 mAb and appeared as
a 44-kD band (Fig. 1 B, lane 1). To further rule out the
possibility that FasL could be present on melanoma cell sur-
face and be functionally active, despite the undetectability
by cytometry and immunoprecipitation analyses, we evalu-
ated the ability of melanoma cells to directly induce apop-
tosis of Fas-positive lymphoid cells. No significant apopto-
sis could be detected by incubating melanoma with Jurkat
cells which, on the contrary, underwent substantial cell
death in the presence of rFasL (Fig. 1 C). The possibility
that FasL undetectability could be caused by massive shed-
ding from cell membrane was further investigated by ana-
lyzing melanoma cell supernatants for the presence of solu-
ble FasL (Fig. 1 D). Concentrated supernatants from
melanoma cell lines were analyzed by Western blot analysis
with G247 mAb and showed no positivity for soluble FasL,
which was on the contrary detected in supernatants from
PHA-activated Jurkat cells as a 27-kD band. The absence
of detectable levels of sFasL was also confirmed by ELISA
(data not shown). The same supernatants from melanoma
did not show any cytotoxic activity when incubated with
Jurkat cells (Fig. 1 C), confirming the absence of any func-
tional proapoptotic molecule.
Immunocytochemical analysis was then performed in
different melanoma cell lines to evaluate possible intracellu-
lar expression of FasL, using G247 mAb. The results of im-
munocytochemistry clearly demonstrated that FasL was ex-
pressed intracellularly by all the melanoma cell lines
examined (data in Fig. 2 refer to three melanoma lines, rep-
resentative of a panel of 10 lines tested). Fig. 2 shows that
the intensity of the staining for FasL varied among melano-
mas and that the staining was invariably localized in defined
endocytic compartments, markedly represented in mela-
noma cells. Intracellular FasL expression was also confirmed
by flow cytometry performed in the same melanoma cell
lines after permeabilization with 70% methanol (Fig. 3 A).
To validate cytochemical and cytofluorimetric data, the
presence of FasL was further evaluated in the total lysate
from melanoma cells. Indeed, Western blot analysis with
the G247 mAb revealed a significant positivity (Fig. 3 B,
lanes 2 and 3), resembling the pattern observed in PHA-
activated Jurkat cells (Fig. 3 C, lane 2). Three major bands
were detected in both melanoma and Jurkat cell lysates,
corresponding to a molecular weight ranging between 40
and 33 kD (as compared with rFasL, estimated molecular
weight 35 kD). This pattern, which is typically observed in
Western blot analysis with G247 mAb (27), likely repre-
sents differently glycosylated forms of FasL molecule. Simi-
lar positivity was observed when cytoplasm-enriched prep-
arations purified by differential centrifugations of total
melanoma cell lysate were tested (Fig. 3 D, lanes 2 and 3).
Figure 3. FasL intracellular localization in melanoma cells. (A) Cytofluorimetric analysis: melanoma cells were permeabilized with 70% methanol for 5
min on ice and subsequently stained with the anti-FasL G247 mAb (dark area) or with an isotype-matched IgG (clear area). Fluorescence was analyzed by
FACSCalibur™ and CELLQuest™ software; data refer to three representative melanoma lines, from a panel of 10 tested. (B and C) Western blot detec-
tion of FasL in melanoma total cell lysates. Melanoma or PHA-activated Jurkat total cell lysates were stained by the anti-FasL G247 mAb. A significant
positivity was detected in melanoma cell lysates (panel B, lanes 2–3), resembling the pattern observed in PHA-activated Jurkat cells (panel C, lane 2).
Three major bands were detected in both melanoma and Jurkat cell lysates, corresponding to a molecular weight ranging between 40 and 33 kD and
likely representing differently glycosylated forms of FasL molecule. (D) Western blot detection of FasL in cytoplasmic fractions of melanoma cells. Cyto-
plasmic-enriched preparations from melanoma cells were obtained as described in Materials and Methods. Western blot was stained with G247 mAb. Sig-
nificant positivity (with bands ranging between 40 and 33 kD, with a predominance of the 40-kD band) was observed in both melanoma lines (lanes 2
and 3).1309 Andreola et al.
However, a clear predominance of the 40-kD band could
be detected in cytoplasmic preparations as compared with
total melanoma cell lysates, possibly due to a higher con-
centration of the mature, glycosylated form of FasL.
Altogether, these data strongly indicate that the expres-
sion of FasL molecules in these tumor cells is mostly con-
fined to the intracellular compartment.
Immunoelectron microscopy analysis was used to further
investigate FasL subcellular localization in human melanoma
cells. The results showed that FasL immunolabeling was
clearly confined to MVB (Fig. 4 A), specialized cellular
compartments displaying internal membrane-bound vesicles
(29). Within the MVB, FasL was expressed by vesicles that
contain melanin in various stages of maturation (Fig. 4 B),
suggesting the melanosomal origin of these structures. With
the aim of further evaluating the nature of the FasL-express-
ing vesicles, we performed double-labeling experiments on
cryosectioned cells. The results showed that FasL positive
vesicles coexpressed both markers of lysosomes (i.e., CD63)
and melanosomes (i.e., gp100). Fig. 4 C shows that MVB of
melanoma cells are double labeled for FasL and CD63,
while Fig. 4 D reports both coexpression of FasL and gp100
by MVB and the absence of staining in other vesicular struc-
tures, such as endoplasmic reticulum (ER). Figs. 4 E shows a
colocalization of CD63 and gp100 in MVB, that was consis-
tent with the costaining of FasL with either CD63 or gp100.
Fig. 4 F is a higher magnification of a MVB showing the
staining for FasL and gp100 in this structure. This set of re-
sults strongly indicates that FasL is localized in MVs coex-
pressing lysosome and melanosome markers and that its ex-
pression can be detected in MVB of melanoma cells.
FasL Expression and Apoptotic Activity of Purified Melano-
somes. On the basis of the immunoelectron microscopy
data, we thus evaluated the expression of FasL on melano-
Figure 4. Immunoelectron microscopic
analysis of FasL expression in human mela-
noma cells. (A and B) Immunoelectron mi-
croscopy obtained by Lowicryl HM20 resin
embedment (see Materials and Methods) of
melanoma cells (bars, 1  m). (A) A multi-
vesicular body containing melanosomes at
different state of maturation labeled for
FasL. (B) Magnification of the squared area
in A, showing the specific FasL labeling on
light and dark organelles corresponding to
early (low melanin levels) and late (high
melanin levels) melanosome differentation
state, respectively. (C–F) Immunoelectron
microscopy pictures obtained by ultrathin
cryosections of melanoma cells (see Materi-
als and Methods) (bars, 0.1  m). (C) Dou-
ble immunolabeling of FasL (large golds, 20
nm; arrow) and CD63 (small golds, 10 nm;
arrowhead); (D) of FasL (large golds, 20 nm;
arrow) and gp100 (small golds, 10 nm; arrow-
head); small arrowheads indicate the ER
free of gold particle staining; (E) double
immunolabeling of CD63 (large golds, 20
nm; arrow) and gp100 (small golds, 10 nm;
arrowhead); (F) higher magnification of a
multivesicular body double stained for FasL
(large golds, 20 nm; arrow) and gp100
(small golds, 10 nm; arrowhead).1310 Tumor Counterattack through FasL-bearing Melanosome-related Vesicles
somes purified from human melanoma cells. Western blot
analysis was performed using proteins derived from mela-
nosomal preparations isolated by sucrose gradient from
the same melanoma lines previously tested for FasL intra-
cellular expression. Staining with G247 mAb revealed the
presence in melanosome preparations of the 40–33-kD
band pattern (Fig. 5 A, lanes 2–4), similar to that detect-
able in melanoma cell lysates and in PHA-activated Jurkat
cells (Fig. 3). These results confirmed the presence of FasL
molecule in melanosome granules from melanoma cells, as
previously suggested by immunocytochemistry and immu-
noelectron microscopy. Controls performed to check pu-
rity of melanosome preparations revealed the expression of
the melanosomal marker gp100, and no significant con-
tamination with Golgi, mitochondria, or plasma-mem-
brane markers (Fig. 5 B). As described previously (30), the
ER marker Bip/GRP78 was detectable in melanosome
preparations (Fig. 5 B) and could not be eliminated by
standard separation procedures. However, being ER-nega-
tive for FasL (Fig. 4 D), the presence of these subcellular
contaminant are unlikely to contribute to FasL detection
in melanosome preparations.
Figure 5. FasL expression in melanosomes purified from melanoma cells. (A) Western blot analysis of purified melanosome preparations. Western blot
analysis was performed using proteins derived from melanosomal preparations purified from melanoma lines by sucrose gradient. Staining with G247
mAb revealed the presence in melanosome preparations of the 40–33 kD band pattern (lane 3–5). (B) Purity controls of melanosome preparations. Con-
trols performed to check purity of melanosome preparations revealed the expression of the melanosomal marker gp100, and no significant contamination
with Golgi, mitochondria, or plasma-membrane markers. The ER marker Bip/GRP78 was detectable in melanosome preparations. (C) Cytofluorimetric
analysis of FasL expression on purified melanosomes. Melanosomes were stained with anti-FasL NOK-1, anti-gp100, anti LAMP-2, and anti-CD63
mAbs, followed by incubation with FITC goat anti–mouse IgG (dark areas); an irrelevant isotype-matched Ab plus the FITC-conjugated goat anti–
mouse IgG were used as negative control (clear areas). Fluorescence was analyzed by FACSCalibur™ and CELLQuest™ software. Melanosomes were
detected as granules of the approximate mean size of 1  m, relative to standard beads of 6  m size.
Figure 6. Induction of Fas-mediated
apoptosis by purified melanosomes. (A)
Jurkat cells were incubated overnight in
the presence of rFasL (100 ng/ml), or dif-
ferent doses of melanosomes (total protein
concentration: 0.35 mg/ml), purified from
501mel melanoma line as described in
Materials and Methods. Cells were incu-
bated alone or after treatment with ZB4
mAb (50 ng/ml) and harvested 18 h later.
Apoptosis was then evaluated by propid-
ium and annexin staining and FACS®anal-
ysis and expressed as percentage of apop-
totic cells. (B) Jurkat cells were pretreated with different concentrations of ZB4 and incubated with 100  l per well melanosomes. Apoptosis was
then evaluated by propidium and annexin staining and FACS®analysis.1311 Andreola et al.
Cytofluorimetric analysis was then performed to further
characterize the antigenic profile, including FasL expression,
of purified melanosomes. As shown in Fig. 5 C, melano-
somes were positive for FasL as detected by NOK-1 mAb,
thus suggesting a possible membrane localization of FasL in
such organelles, along with the melanosomal molecule
gp100, and the lysosomal markers LAMP-2 and CD63.
Then, we performed experiments aimed at evaluating
the functional role of FasL expressed in melanosomes. To
investigate the possible proapoptotic activity of melanoma-
derived melanosomes, purified preparations were tested for
induction of Fas-mediated apoptosis in FasL-sensitive Jurkat
cells. Indeed, melanosomes induced significant and dose-
dependent apoptosis of Jurkat cells, as detected by cytofluo-
rimetric analysis with propidium and annexin staining (Fig.
6 A). The observed apoptosis was indeed FasL-mediated,
since it could be significantly inhibited by preincubation of
target cells with different concentrations of the anti-Fas
mAb ZB4 (Fig. 6 A and B). ZB4-mediated inhibition of
apoptosis appeared to be more effective with rFasL as com-
pared with melanosomes, suggesting the presence in mel-
anosome preparations of a higher concentration either of
bioactive FasL or bystander proteins, possibly impairing Ab
binding efficiency. In any case, these results provide evi-
dence for the presence of functionally active FasL molecules
in melanosomes derived from melanoma cells.
Release of MVs by Melanoma Cells and their Apoptotic Activ-
ity. Previous studies have shown that a secretion of MVs,
or exosome-like particles, underlies the formation of MVB
in various cells types (29). Thus, we performed a series of
experiments aimed at evaluating the possible secretion of
MVs expressing FasL by human melanoma cells. A pre-
liminary analysis by immunocytochemistry showed that
human melanoma cells cultured in chamber-slides exerted
a straightforward polarization of FasL staining on their in-
terdigitated structures (Fig. 7 A). Further observations sug-
gested a secretory behavior of the FasL-bearing MVs (Fig.
7 B) and in some cases revealed FasL-positive MVB-like
structures with a clear secretory behavior, together with
the presence of clusters of FasL-positive vesicles 8–10 mm
away from the plasma membrane of melanoma cells (Fig. 7
C). Immunocytochemistry is not suitable for the demon-
stration of the MVB secretory behavior, nor for the identi-
fication of exosome-like particles. Thus, we performed im-
munoelectron microscopy in order to define both MVB
secretory activity and the presence of FasL-bearing vesicles
in human melanoma cells. Fig. 8 A and B clearly show that
FasL-immunolabeled MVs degranulate from MVB of mel-
anoma cells in the extracellular environment. Fig. 8 B also
shows that the ER beneath the plasma membrane does not
stain for FasL.
These particles, as well as their secretory pathway, highly
resembled those described in various immunocompetent
cells (15, 16). Thus, we performed experiments aimed at
obtaining purified preparations of MVs from melanoma cell
supernatant. Immunoelectron microscopy analysis of the
pellets obtained by sequential ultracentrifugation of mela-
noma cell culture supernatant revealed the presence of ves-
Figure 7. Immunocytochemical analysis of MVs released by melanoma
cells. (A) A cluster of human melanoma cells adherent on glass chamber
slides, showing a high level of FasL expression (as detected by G247
mAb), polarized on cellular filopodia and interdigitations (arrowheads).
(B) Higher magnification of the FasL stainings on the tip of a melanoma
cell interdigitation, showing both the unidirectional secretory behavior
(arrowhead) and the marked polar concentration (arrow) of the FasL
staining. (C) High electronic magnification of a defined field of a mela-
noma cell where a cluster of FasL-positive vesicles is under degranulation
and a group of three isolated FasL-positive vesicles is detectable 8–10  m
away from the cell membrane (arrow). Immunophenotyping of fixed cells
was performed using the PAP method; AEC was used as chromogen and
Mayer’s haematoxylin for the counterstaining. Final original magnifica-
tions: (A) 1,000 ; (B) 2,500 ; and (C) 3,000 .1312 Tumor Counterattack through FasL-bearing Melanosome-related Vesicles
icles of 100–200 nm in size showing a marked positivity for
FasL (Fig. 8 C), CD63 (Fig. 8 D), and gp100 (Fig. 8 E)
stainings, being negative for the Golgi immunolabeling
(Fig. 8 F). The vesicles, often detectable as aggregates, were
morphologically similar to those contained in the MVB
and excreted extracellularly (Fig. 8 A and B).
Analysis of MVs isolated from melanoma cell superna-
tant, as performed by Western blot, showed that FasL was
indeed detectable (Fig. 9 A, lanes 4, 6, and 7) in such prep-
arations, with an  35-kD band, highly resembling the one
observed in MVs from PHA-activated Jurkat cells (Fig. 9
A, lane 2).
It should be noted that FasL expressed in microvesicle
preparations did derived from melanoma and activated Jur-
kat cells, respectively, and not from FBS present in culture
media. In fact, only MVs isolated from PHA-activated Jur-
kat cells showed strong positivity for FasL, while no posi-
tivity was detected in MVs isolated from nonactivated cells
(Fig. 9 A, lane 3), maintained under the same culture con-
ditions (i.e., in 10% FBS). Further analysis of melanoma-
derived MVs showed the concomitant expression in these
preparations of the melanosomal marker gp100 (Fig. 9 B)
and the absence of any ER, Golgi, and mitochondria mark-
ers (Fig. 9 B). These vesicles resulted positive for class I
HLA expression, as expected (19), but showed no positiv-
ity for caveolin, which was however detectable in purified
melanoma cell membranes (data not shown).
On particulate, ultracentrifugable fractions from mela-
noma cell supernatants we additionally performed FACS®
analysis, which confirmed the presence of MVs (with a di-
ameter   100 nm) expressing FasL, in addition to melano-
somal and lysosomal antigens (gp100, LAMP-2, and CD63)
(Fig. 9 C).
Experiments were finally performed to assess the proap-
optotic activity of the MVs by exploiting the same approach
used for melanosomes. The results clearly showed that pu-
rified MVs from melanoma cells expressed bioactive FasL
and induced ZB4-blockable, thus Fas-mediated apoptosis
of Jurkat cells, as detected by propidium and annexin stain-
ing (Fig. 10 A). However, the observed apoptosis was sig-
nificantly lower than that mediated by MVs derived from
PHA-activated Jurkat cell supernatants, suggesting a less ef-
Figure 8. Immunoelectron microscopy analysis of mul-
tivesicular bodies, secretory vesicles, and isolated MVs
from melanoma cells. (A and B) Immunoelectron micros-
copy on ultrathin cryosections of human melanoma cells
(see Materials and Methods). (A) Note the clear FasL immu-
nolabeling of exosome-like particles (arrows) degranulating
in the extracellular environment by a multivesicular body.
In B, multiple degranulation sites are shown with FasL
immunolabeled exosome-like vesicles (arrows) scattered
into the extracellular environment. Arrowheads outline a
wide ER vesicle (ER) that appears negative for the FasL
immunolabeling. (C–F) Electron microscopy of the
100,000 g pellet immunogold labeled for (C) FasL, (D)
CD63, (E) gp100, and (F) Golgi, respectively. The pellet
was composed of 100–200 nm MVs, often detected as
aggregates, showing abundant FasL, CD63, and gp100
immunolabeling, while they do not stain for Golgi markers
(bars, 0.1  m).1313 Andreola et al.
ficient activity in melanoma as compared with immune
competent cells. Specificity of Jurkat apoptosis induced by
melanoma-derived MVs was further confirmed by the
dose-dependent inhibition obtained in the presence of the
anti-Fas mAb ZB4 (Fig. 10 B). An additional evidence for
the induction of a specific apoptotic pathway was provided
by the analysis of caspase-8 activation, that showed the ap-
pearance of the cleaved activated form of 40 kD after incu-
bation with both melanoma-derived MVs and isolated
melanosomes, undetectable though when Jurkat cells were
pretreated with ZB4 (Fig. 10 C).
These functional data suggest that melanoma cells can
release MVs which retain the functional and phenotypic
pattern observed in cytoplasmatic melanosomes and can
exert FasL-dependent proapoptotic activity on Fas-sensi-
tive target cells.
Discussion
In this study, we describe a novel pathway of tumor
counterattack through the secretion by melanoma cells of
FasL-positive MVs, highly supporting the role of FasL in
tumor escape from immune effector cells. The results of
our study show that (i) FasL is indeed expressed in the
cytoplasm of human melanoma cells; (ii) its expression is
confined to MVB where FasL is coexpressed with both
melanosomal and lysosomal markers; (iii) purified
melanosomes are able to induce a Fas-mediated apoptosis
in Fas-sensible human T cells; and (iv) melanosomes may
undergo a secretory pathway through MVB, which also re-
lease MVs expressing FasL, melanosomal, and lysosomal
markers and inducing Fas-mediated T cell apoptosis. These
results clearly conciliate the opposite views on the FasL-
mediated cancer counterattack, since they provide a com-
prehensive explanation to the controversial issue on FasL
expression by tumor cells. In fact, we confirm the absence
of detectable FasL expression at cell membrane level and
the lack of proapoptotic activity mediated by whole mela-
noma cells, as reported by some authors (7, 8). At the same
time, however, we provide an explanation for other results
showing the presence of detectable levels of FasL in the in-
tracellular compartment of tumor cells (10) and the prog-
nostic role of FasL in tumor progression (5, 6, 9, 14).
The expression of FasL in lysosome-related vesicles or
other secretory granules has been indeed reported as a fea-
ture of immunocompetent cells (15, 16). However, the
MVB of melanoma cells showed some peculiarities, such as
the presence of melanosome-like electrondense vesicles, se-
creted in the extracellular environment as FasL-positive
vesicles detectable by both immunocytochemistry and im-
munoelectron microscopy. Microvescicles can be separated
from melanoma cell culture supernatant and are able to
trigger Fas-mediated apoptosis of sensitive human lym-
phoid target cells. Notably, these MVs displayed lysosomal
features in terms of expression of lysosomal antigens such as
CD63 and LAMP-2 and showed morphological features
similar to those described in immunocompetent cells (15,
16). On the basis of our data, we cannot rule out the possi-
bility that vesicles of a size inferior to the detection limit of
cytofluorimetric analysis (presently classified as ‘exosomes’)
could be also present in our melanoma supernatants. In
fact, the evidence of MVB formation in melanoma cells,
Figure 9. FasL expression on MVs purified from
melanoma cell supernatant. (A) Western blot analy-
sis. Analysis of MVs isolated from melanoma cell su-
pernatant by serial ultracentrifugations, as performed
by Western blot and staining with G247 mAb. An
 35-kD band can be observed in MVs from mela-
noma lines (lanes 4, 6, and 7), resembling the one
observed in MVs from PHA-activated Jurkat cells
(lane 2). Only MV from PHA-activated, and not
from resting Jurkat cells (lane 3) showed positivity
for FasL, suggesting that this molecule unlikely derived from FBS used for cell culture. (B) Purity controls of microvesicle preparations. Controls performed
to check purity of microvesicle preparations from melanoma cell supernatant revealed the expression of the melanosomal marker gp100, and no significant
contamination with Golgi, ER, or mitochondria. (C) Cytofluorimetric analysis of FasL expression on purified MVs. MVs from 501mel line were stained
with anti-FasL NOK-1, anti-gp100, anti–LAMP-2, and anti-CD63 mAbs, followed by incubation with FITC goat anti–mouse IgG (dark areas); an irrelevant
isotype-matched Ab plus the FITC-conjugated goat anti–mouse IgG were used as negative control (clear areas). Fluorescence was analyzed by FACSCalibur™
and CELLQuest™ software. MVs were detected as granules with a size range of 100–600 nm, relative to standard beads of 6  m size.1314 Tumor Counterattack through FasL-bearing Melanosome-related Vesicles
together with the information from immunoelectron mi-
croscopy on supernatant ultracentrifugates, suggest that ex-
osome-like particles, known to be released by melanoma
cells (19) and by other cell types (29, 31), may contribute
to the phenomenon of microvesicle-induced FasL-medi-
ated apoptosis here described.
The release of membrane-associated FasL through se-
cretion of intracellular organelles represents an effective
mechanism for mediating apoptosis, given the higher effi-
ciency in triggering Fas-mediated apoptosis of membrane-
linked FasL as compared with its soluble form (32) and the
evidence that conversion of membrane FasL to its soluble
form leads to downregulation of the proapoptotic activity
(33). A vectorial transport of FasL has been recently de-
scribed on lysosomal-like vesicles in NK and T cells (15,
16). On the basis of these data it has been hypothesized
that this targeting of FasL to the secretory lysosomes is spe-
cific to cells of hematopoietic lineage, as a sort of tight reg-
ulatory mechanism of FasL expression in cells that are
committed to kill target cells through the Fas-mediated
pathway (15). This is further supported by studies showing
that FasL is stored in the secretory granules of monocytes
(34). However, it is well known that melanosomes, as well
as lytic granules of NK cells and phagosomes, belong to
the family of the lysosomal-like organelles, expressing the
same lysosomal-associated antigens (18). We describe here
FasL-expressing melanosome-like organelles secreted by
human melanoma cells as vesicles able to deliver a Fas-
mediated cell death to Fas-sensible lymphoblastoid cells.
These data suggest that melanoma cells may share with
NK cells, and probably with monocytes, (i) a similar path-
way of FasL targeting to lysosomal-like particles and (ii) a
similar secretory pathway of these particles mediating a
Fas-mediated cell death that does not necessarily imply a
cell-to-cell contact. It seems hence conceivable that secre-
tion of FasL-expressing MVs can be a more efficient
mechanism in inducing apoptosis of Fas-expressing cells,
and that this mechanism may well operate in physiologic
(NK, CTL, monocytes, dendritic cells) as well as in aber-
rant (tumor cells) conditions. In fact, it has been suggested
that the cytoplasmic tail of FasL expressed in hematopoi-
etic cells contains a sorting motif that targets the protein to
secretory lysosomes. Additionally, this specialized motif
appears to be shared by other members of the TNF family
(e.g., CD40L; reference 35). On the basis of these consid-
erations it has been further speculated that the accumula-
tion of proteins in the secretory lysosomes may represent a
generalized mechanism for the control of the release of
proteins involved in the regulation of the immune re-
sponse. Since tumor cells may lack such type of tight con-
trol, it is thus conceivable that melanoma cells could
mediate a continuous release and/or degranulation of FasL-
bearing vesicles that indiscriminately kill all the Fas-sensi-
ble cells encountered in the extracellular environment.
This phenomenon would have no consequences on mela-
noma cells, being these cells insensitive to Fas triggering,
and therefore refractory to the autocrine FasL-vesicles-
induced cell death (26, 36, 37). On the basis of our data, it is
still unclear whether the induction of lymphocyte death by
FasL-bearing MVs could be a specific feature of melanoma
cells or it could be shared by other tumors. In fact, al-
though in some histological types (e.g., colon carcinoma)
this molecule has been located exclusively in the cyto-
plasm, other tumors, such as squamous cell carcinoma,
Figure 10. Apoptotic activity of MVs isolated from melanoma cell supernatant. (A) Jurkat
cells were incubated overnight in the presence of rFasL (100 ng/ml), or 50  l/ml MVs iso-
lated from resting Jurkat cells, PHA-activated Jurkat cells or 501mel cells, purified as de-
scribed in Materials and Methods (protein concentrations: 13.3, 15, and 5.1 mg/ml, respec-
tively). Target cells were used with or without pretreatment with ZB4 mAb (50 ng/ml) and
harvested 18 h later. Evaluation of apoptosis induction as detected by FACS® analysis for
propidium and annexin staining. (B) Jurkat cells were pretreated with different concentra-
tions of ZB4 and incubated with rFasL (100 ng/ml) or 50  l per well MVs from 501mel
line. Apoptosis was then evaluated by propidium and annexin staining and FACS®analysis.
(C) Western blot analysis of caspase-8 cleavage. Control loading is shown by actin. Jurkat
cells, with (Jurkat/ZB4) or without preexposure to ZB4 mAb (50 ng/ml), were incubated
overnight with different apoptotic stimuli: lane 1, Jurkat; 2, Jurkat/ZB4; 3, Jurkat   rFasL
(100 ng/ml); 4, Jurkat/ZB4 plus rFasL; 5, Jurkat plus melanosomes (100  l/ml, protein concentration 3.5 mg/ml); 6, Jurkat/ZB4 plus melanosomes; 7,
Jurkat plus 501mel MVs (50  l/ml, protein concentration 5.1 mg/ml); Jurkat/ZB4 plus 501mel MVs. Induction of apoptosis was detected as a 40-kD
band, representing the cleaved activated form of activated caspase-8. No band is detectable when Jurkat cells were pretreated with ZB4.1315 Andreola et al.
have been clearly shown to stably express FasL at the
plasma membrane level (11).
Our data support the relevance of FasL-mediated apop-
tosis in tumor evasion from immunological control. Other
mechanisms can play a significant role in reducing the in
vivo efficacy of CTL response to melanoma antigens (1)
and antitumor T cell subpopulations resistant to FasL-induced
apoptosis have been identified at least in vitro (26). How-
ever, this functional pathway of inducing lymphocyte apop-
tosis through the release of FasL-positive MVs may indeed
play a significant role in eliminating the most effective
component of the antitumor T cell response in vivo.
While we cannot rule out the possibility that FasL-bear-
ing granules could instead deliver proinflammatory signals,
as indeed described in other experimental systems (38, 39),
it is likely, given the natural history of neoplastic disease,
that this mechanism may contribute in tilting the balance
toward an immunosuppressive environment at tumor site.
Thus, we believe that future studies aimed at understand-
ing the mechanism responsible for this phenomenon, to-
gether with the identification of therapeutical strategies for
specifically inhibiting tumor exocytosis, could contribute
to ameliorate immunological control of tumor growth in
cancer patients.
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